First patient receives HeartAssist5 VAD following CE mark approval

Published on:

Privately-held ReliantHeart, a leading innovator in mechanical circulatory support therapies, today announced the first advanced stage heart failure patient received its next generation HeartAssist5 Ventricular Assist Device (VAD) since the company earned CE Mark approval for design enhancements just weeks ago.  Cardiologists at the Deutsches Herzzentrum Berlin (DHZB - German Heart Institute) in Germany performed the life-saving procedure.

"The quick acceptance and use of our support device following CE Mark approval speaks volumes and sets us on our path to restoring health and extending the life of millions of people suffering from heart failure worldwide," said Rodger Ford, president and CEO of ReliantHeart.

Implanted above the diaphragm and weighing just 3.3 ounces, this next generation ventricular assist device offers natural human pulse circulation support to the weakened heart.

Unique to the HeartAssist5 is its 24/7 HeartAssistRemote(tm) Monitoring System which continuously receives and transmits patient data to expert clinicians. Combined with a proprietary true-flow measurement system, these optimized device features allow for faster and more precise diagnosis of potential issues.

The HeartAssist5 is commercially available in Europe and is considered an Investigational Device in the USA by the Food and Drug Administration (FDA).  The US clinical trial is expected to start in late 2014.

Related Content

Medtronic using AI to identify more TAVR patients in need
Tirzepatide linked to significant weight loss, ‘impressive’ diabetes prevention after 3 years
Most heart failure patients miss out on guideline-recommended palliative care
CMS updates outpatient reimbursement policy for Barostim device
American Heart Association announces late-breaking research for Scientific Sessions 2024
Impella ECP confirmed to be safe for high-risk PCI—is FDA approval next?

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."